Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 4.862
Filter
3.
Int J Mol Sci ; 25(17)2024 Aug 29.
Article in English | MEDLINE | ID: mdl-39273332

ABSTRACT

This case report concerns a 48-year-old man with a history of ischemic stroke at the age of 41 who reported cardiac hypertrophy, registered in his twenties when explained by increased physical activity. Family history was positive for a mother with permanent atrial fibrillation from her mid-thirties. At the age of 44, he had a first episode of persistent atrial fibrillation, accompanied by left atrial thrombosis while on a direct oral anticoagulant. He presented at our clinic at the age of 45 with another episode of persistent atrial fibrillation and decompensated heart failure. Echocardiography revealed a dilated left atrium, reduced left ventricular ejection fraction, and an asymmetric left ventricular hypertrophy. Cardiac magnetic resonance was positive for a cardiomyopathy with diffuse fibrosis, while slow-flow phenomenon was present on coronary angiography. Genetic testing by whole-exome sequencing revealed three variants in the patient, c.309C > A, p.His103Gln in the ACTC1 gene, c.116T > G, p.Leu39Ter in the PLN gene, and c.5827C > T, p.His1943Tyr in the SCN5A gene, the first two associated with hypertrophic cardiomyopathy and the latter possibly with familial atrial fibrillation. This case illustrates the need for advanced diagnostics in unexplained left ventricular hypertrophy, as hypertrophic cardiomyopathy is often overlooked, leading to potentially debilitating health consequences.


Subject(s)
Atrial Fibrillation , Cardiomyopathy, Hypertrophic , Hypertrophy, Left Ventricular , Humans , Atrial Fibrillation/genetics , Atrial Fibrillation/diagnosis , Male , Middle Aged , Cardiomyopathy, Hypertrophic/genetics , Cardiomyopathy, Hypertrophic/diagnosis , Cardiomyopathy, Hypertrophic/complications , Hypertrophy, Left Ventricular/genetics , Hypertrophy, Left Ventricular/diagnosis , Stroke/genetics , Stroke/diagnosis , Echocardiography , NAV1.5 Voltage-Gated Sodium Channel/genetics
4.
Arq. bras. cardiol ; 121(9 supl.1): 114-114, set.2024. ilus
Article in Portuguese | CONASS, Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP | ID: biblio-1568107

ABSTRACT

INTRODUÇÃO: A Cardiomiopatia Hipertrófica (CMH) é a doença cardíaca genética mais comum, com prevalência em 1 a cada 500 pessoas. A principal característica é a hipertrofia ventricular esquerda na ausência de patologias que justifiquem tal alteração. A CMH pode apresentar desde formas assintomáticas até insuficiência cardíaca refratária e morte súbita cardíaca (MSC). Possui padrão de herança autossômica dominante com expressividade e penetrância variáveis. Para diagnóstico e estratificação do risco de MSC dispõe-se do Eletrocardiograma (ECG), Ecocardiograma (ECOTT), Holter 24h, Teste Ergométrico (TE), Ressonância Magnética (RM) e Testes Genéticos. RELATO DE CASO: A.O.A, 60 anos, natural de SP, dislipidêmico, ex- atleta profissional de corridas de curta distância, que se aposentou aos 40 anos. Encaminhado ao ambulatório de Cardiologia do Esporte do Instituto Dante Pazzanese de Cardiologia para avaliação. Praticante de corridas de rua 3x/semana, treinos de 10-12km. Negou sintomas, assim como histórico de doenças cardiovasculares na família. ECG: Ritmo sinusal, sinais de sobrecarga ventricular esquerda com alterações da repolarização ventricular difusas (ondas T's profundas). Exame físico sem alterações. Aventada hipótese diagnóstica de CMH e optado por suspender atividades físicas até realização dos exames. ECOTT evidenciou cavidades normais, espessura miocárdica preservada, função preservada, sem anormalidades valvares. RM fibrose ou hipertrofia miocárdica. TE mostrou boa capacidade funcional e ausência de arritmias esforço induzidas. Alterações eletrocardiográficas persistentes apesar do destreinamento. Mantido acompanhamento regular devido à possibilidade de manifestação de CMH. Após 6 anos, novo ECOTT evidenciou hipertrofia assimétrica, septo 12mm e parede posterior de 9mm. Realizada RM, a qual mostrou hipertrofia septal simétrica apical (14mm) com padrão de fibrose mesocárdica na porção apical da parede inferior. CONCLUSÃO: No presente relato, apesar do ECG muito sugestivo de CMH, demais exames não apresentaram alterações significativas. Todavia a doença possui expressividade e penetrância variáveis, podendo se manifestar ao longo da vida e as alterações eletrocardiográficas podem anteceder as alterações estruturais cardíacas. Por isso, é de extrema importância acompanhar esses pacientes e, assim, atuar na prevenção da MSC. No presente relato de caso as alterações eletrocardiográficas antecederam em 6 anos as alterações apresentadas na segunda RM.


Subject(s)
Cardiomyopathy, Hypertrophic/diagnosis
5.
Turk Kardiyol Dern Ars ; 52(6): 455-459, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39225642

ABSTRACT

Takotsubo cardiomyopathy (TCM) is characterized by transient left ventricular dysfunction, diagnosed via echocardiography or left ventriculography. In most cases, TCM involves an emotional, physical, or combined trigger. Acute coronary syndrome is one of the most frequent misdiagnoses in TCM patients due to electrocardiogram (ECG) abnormalities and elevated cardiac biomarkers. Typically, coronary angiography reveals no stenosis or occlusion of the coronary arteries. Hypertrophic cardiomyopathy (HCM) is a distinct pathology characterized by a hypertrophied left ventricle with various phenotypes. However, some reports have described TCM cases mimicking obstructive-type HCM in some patients. We present a case of a female patient diagnosed with TCM based on clinical, laboratory, and imaging tests. Differentiating TCM from HCM was challenging due to ventriculography and echocardiography findings, as hyperdynamic contraction of the basal segments of the left ventricle caused an increased left ventricular outflow tract (LVOT) gradient and severe mitral valve regurgitation. Detailed evaluation and close echocardiographic follow-up are essential in such rare cases.


Subject(s)
Cardiomyopathy, Hypertrophic , Electrocardiography , Takotsubo Cardiomyopathy , Humans , Takotsubo Cardiomyopathy/diagnosis , Takotsubo Cardiomyopathy/diagnostic imaging , Takotsubo Cardiomyopathy/physiopathology , Female , Cardiomyopathy, Hypertrophic/diagnosis , Cardiomyopathy, Hypertrophic/diagnostic imaging , Cardiomyopathy, Hypertrophic/physiopathology , Diagnosis, Differential , Echocardiography , Middle Aged
6.
J Cell Mol Med ; 28(16): e70034, 2024 Aug.
Article in English | MEDLINE | ID: mdl-39160643

ABSTRACT

Hypertrophic cardiomyopathy (HCM) is a hereditary cardiac disorder marked by anomalous thickening of the myocardium, representing a significant contributor to mortality. While the involvement of immune inflammation in the development of cardiac ailments is well-documented, its specific impact on HCM pathogenesis remains uncertain. Five distinct machine learning algorithms, namely LASSO, SVM, RF, Boruta and XGBoost, were utilized to discover new biomarkers associated with HCM. A unique nomogram was developed using two newly identified biomarkers and subsequently validated. Furthermore, samples of HCM and normal heart tissues were gathered from our institution to confirm the variance in expression levels and prognostic significance of GATM and MGST1. Five novel biomarkers (DARS2, GATM, MGST1, SDSL and ARG2) associated with HCM were identified. Subsequent validation revealed that GATM and MGST1 exhibited significant diagnostic utility for HCM in both the training and test cohorts, with all AUC values exceeding 0.8. Furthermore, a novel risk assessment model for HCM patients based on the expression levels of GATM and MGST1 demonstrated favourable performance in both the training (AUC = 0.88) and test cohorts (AUC = 0.9). Furthermore, our study revealed that GATM and MGST1 exhibited elevated expression levels in HCM tissues, demonstrating strong discriminatory ability between HCM and normal cardiac tissues (AUC of GATM = 0.79; MGST1 = 0.86). Our findings suggest that two specific cell types, monocytes and multipotent progenitors (MPP), may play crucial roles in the pathogenesis of HCM. Notably, GATM and MGST1 were found to be highly expressed in various tumours and showed significant prognostic implications. Functionally, GATM and MGST1 are likely involved in xenobiotic metabolism and epithelial mesenchymal transition in a wide range of cancer types. GATM and MGST1 have been identified as novel biomarkers implicated in the progression of both HCM and cancer. Additionally, monocytes and MPP may also play a role in facilitating the progression of HCM.


Subject(s)
Biomarkers , Cardiomyopathy, Hypertrophic , Machine Learning , Neoplasms , Humans , Cardiomyopathy, Hypertrophic/metabolism , Cardiomyopathy, Hypertrophic/diagnosis , Cardiomyopathy, Hypertrophic/genetics , Neoplasms/metabolism , Neoplasms/diagnosis , Neoplasms/genetics , Neoplasms/pathology , Biomarkers/metabolism , Male , Female , Prognosis , Biomarkers, Tumor/metabolism , Biomarkers, Tumor/genetics , Middle Aged , Nomograms
8.
Curr Probl Cardiol ; 49(11): 102786, 2024 Nov.
Article in English | MEDLINE | ID: mdl-39122099

ABSTRACT

Hypertrophic obstructive cardiomyopathy (HOCM) is an autosomal dominant condition that still remains significantly under-diagnosed worldwide. Early detection through clinical evaluation, imaging, and familial history is crucial to prevent severe complications such as heart failure and sudden cardiac death. While cuddsnt management strategies primarily offer symptomatic relief through pharmacotherapy or invasive procedures, their effectiveness and accessibility are limited, revealing substantial gaps in care. The emergence of Mavacamten, a recently FDA-approved drug, could potentially revolutionize HOCM management as it addresses the underlying pathophysiology by inhibiting cardiac myosin ATPase, showing promise in reducing obstruction and improving cardiac function. Our review aims to assess mavacamten's efficacy, emphasizing the pivotal role of genetic testing in identifying at-risk individuals and guiding precise diagnoses for personalized treatments. Additionally, we aim to highlight disparities in access to advanced diagnostics and therapies, particularly affecting underserved populations globally and within communities, as well as explore the potential of artificial intelligence (AI) in enhancing early detection and monitoring treatment responses in HOCM. This review thus offers valuable insights to inform future research directions and clinical practices aimed at optimizing outcomes for individuals with HOCM.


Subject(s)
Artificial Intelligence , Cardiomyopathy, Hypertrophic , Healthcare Disparities , Humans , Cardiomyopathy, Hypertrophic/diagnosis , Cardiomyopathy, Hypertrophic/therapy , Uracil/analogs & derivatives , Uracil/therapeutic use , Benzylamines
9.
Tex Heart Inst J ; 51(2)2024 Aug 01.
Article in English | MEDLINE | ID: mdl-39086311

ABSTRACT

Despite substantial advances in the management of hypertrophic cardiomyopathy, advanced heart failure remains a major cause of morbidity in this patient population. This narrative review presents the case of a patient with hypertrophic obstructive cardiomyopathy who underwent alcohol septal ablation to frame a discussion of modern therapies for hypertrophic cardiomyopathy. The current treatment landscape includes medications, both old and new, and surgical and procedural interventions to relieve mechanical obstruction. Several promising new modalities for relieving obstruction are in the nascent stages of development.


Subject(s)
Ablation Techniques , Cardiomyopathy, Hypertrophic , Humans , Cardiomyopathy, Hypertrophic/therapy , Cardiomyopathy, Hypertrophic/diagnosis , Cardiomyopathy, Hypertrophic/physiopathology , Cardiomyopathy, Hypertrophic/complications , Cardiomyopathy, Hypertrophic/surgery , Ablation Techniques/methods , Male , Treatment Outcome , Ethanol/therapeutic use , Middle Aged
10.
BMC Cardiovasc Disord ; 24(1): 416, 2024 Aug 10.
Article in English | MEDLINE | ID: mdl-39127628

ABSTRACT

BACKGROUND: Patients with obstructive hypertrophic cardiomyopathy (oHCM) have a substantial humanistic, clinical, and economic burden due to the array of symptoms and complications associated with the disease. The objective of this review was to identify key evidence gaps related to oHCM, specifically in Europe, North America, and Japan. METHODS: A targeted literature review was conducted using PubMed to identify English-language studies published between 2012 and 2022 assessing patients with HCM/oHCM in France, Germany, Italy, Spain, the United Kingdom (UK), the United States (US), Canada, and Japan. Outcomes of interest were epidemiology, natural history, pathophysiology, management, and clinical, economic, and humanistic burden. Identified studies were assessed qualitatively to characterize evidence gaps. RESULTS: Among 2,262 abstracts and 531 full-text articles screened, 178 articles were included from PubMed searches. An additional 16 unique studies were identified via a supplemental Google Scholar search initially conducted in January 2023 and updated in July 2024. Disease natural history, pathophysiology, and management were well documented globally. Significant evidence gaps were noted for the epidemiology, treatment, and burden of oHCM. Although multiple US studies were identified on the clinical, economic, and humanistic burden of oHCM, and one clinical burden study was found for Japan, there was a lack of evidence for France, Germany, Italy, Spain, the UK, and Canada. CONCLUSIONS: Major evidentiary gaps exist for the epidemiology, treatment, and burden of oHCM. Future research should address these gaps, with a specific focus on generating real-world evidence for Canada and European countries that will support the evaluation of emerging therapies in these regions.


Subject(s)
Cardiomyopathy, Hypertrophic , Humans , Cardiomyopathy, Hypertrophic/epidemiology , Cardiomyopathy, Hypertrophic/physiopathology , Cardiomyopathy, Hypertrophic/therapy , Cardiomyopathy, Hypertrophic/diagnosis , Health Care Costs , Cost of Illness , Europe/epidemiology , Male
14.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao ; 46(3): 377-383, 2024 Jun.
Article in Chinese | MEDLINE | ID: mdl-38953261

ABSTRACT

Objective To analyze the research progress and hot topics in hypertrophic cardiomyopathy from 2018 to 2022.Methods The publications in the field of hypertrophic cardiomyopathy from January 1,2018 to December 31,2022 were retrieved from Web of Science core collection database and included for a bibliometric analysis.Results A total of 6355 publications were included,with an average citation frequency of 7 times.The year 2021 witnessed the most publications (1406).The analysis with VOSviewer showed that the research on sudden death related to hypertrophic cardiomyopathy,especially the predictive value of late gadolinium-enhanced cardiac MRI in sudden death,was a hot topic.In addition,gene detection and the new drug mavacamten became hot research topics.The United States was the country with the largest number of publications and the highest citation frequency in this field.Chinese scholars produced the second largest number of publications,which,however,included few high-quality research results.Conclusions Risk stratification and prevention of sudden death is still an important and hot research content in the field of hypertrophic cardiomyopathy.Chinese scholars should carry out multi-center cooperation in the future to improve the research results.


Subject(s)
Bibliometrics , Cardiomyopathy, Hypertrophic , Cardiomyopathy, Hypertrophic/epidemiology , Cardiomyopathy, Hypertrophic/diagnostic imaging , Cardiomyopathy, Hypertrophic/diagnosis , Humans , Death, Sudden, Cardiac/epidemiology , Publications/statistics & numerical data , China/epidemiology
15.
J Pak Med Assoc ; 74(6 (Supple-6)): S69-S72, 2024 Jun.
Article in English | MEDLINE | ID: mdl-39018143

ABSTRACT

Symptoms of apical hypertrophic cardiomyopathy (ApHCM) can mimic acute myocardial infarction (AMI). Following COVID-19 infection, the elevation of troponin in ApHCM might be confusing, due to its similarity with AMI. We report the case of a 64-year-old male patient presenting with exertional dyspnoea and chest discomfort. He had no history of coronary artery disease (CAD), but his swab test was positive for COVID-19. The physical examination was normal. The 12-lead electrocardiogram showed a sinus rhythm of 78 bpm, with deep inverted T waves in leads V2 to V6, I, and aVL, and left ventricular hypertrophy. An Echocardiographic examination showed an 18 mm apical wall thickness of the left ventricle. Laboratory tests revealed elevated hs- Troponin level, but diagnostic coronary angiography was normal. The diagnostic criteria fulfilled apical cardiac hypertrophic cardiomyopathy. Coronavirus can induce atypical cardiovascular symptoms in pre-existing ApHCM. Misdiagnosis and failure to recognize may result in inappropriate therapy and delay in definitive treatment.


Subject(s)
COVID-19 , Cardiomyopathy, Hypertrophic , Electrocardiography , Myocardial Infarction , Humans , Male , COVID-19/complications , COVID-19/diagnosis , Middle Aged , Myocardial Infarction/diagnosis , Diagnosis, Differential , Cardiomyopathy, Hypertrophic/diagnosis , Echocardiography , SARS-CoV-2 , Apical Hypertrophic Cardiomyopathy
16.
Int J Mol Sci ; 25(14)2024 Jul 10.
Article in English | MEDLINE | ID: mdl-39062799

ABSTRACT

A genetic diagnosis of primary cardiomyopathies can be a long-unmet need in patients with complex phenotypes. We investigated a three-generation family with cardiomyopathy and various extracardiac abnormalities that had long sought a precise diagnosis. The 41-year-old proband had hypertrophic cardiomyopathy (HCM), left ventricular noncompaction, myocardial fibrosis, arrhythmias, and a short stature. His sister showed HCM, myocardial hypertrabeculation and fibrosis, sensorineural deafness, and congenital genitourinary malformations. Their father had left ventricular hypertrophy (LVH). The proband's eldest daughter demonstrated developmental delay and seizures. We performed a clinical examination and whole-exome sequencing for all available family members. All patients with HCM/LVH shared a c.4411-2A>C variant in ALPK3, a recently known HCM-causative gene. Functional studies confirmed that this variant alters ALPK3 canonical splicing. Due to extracardiac symptoms in the female patients, we continued the search and found two additional single-gene disorders. The proband's sister had a p.Trp329Gly missense in GATA3, linked to hypoparathyroidism, sensorineural deafness, and renal dysplasia; his daughter had a p.Ser251del in WDR45, associated with beta-propeller protein-associated neurodegeneration. This unique case of three monogenic disorders in one family shows how a comprehensive approach with thorough phenotyping and extensive genetic testing of all symptomatic individuals provides precise diagnoses and appropriate follow-up, embodying the concept of personalized medicine. We also present the first example of a splicing functional study for ALPK3 and describe the genotype-phenotype correlations in cardiomyopathy.


Subject(s)
Pedigree , Humans , Female , Male , Adult , Cardiomyopathies/genetics , Cardiomyopathies/diagnosis , Exome Sequencing , Abnormalities, Multiple/genetics , Hearing Loss, Sensorineural/genetics , Phenotype , Cardiomyopathy, Hypertrophic/genetics , Cardiomyopathy, Hypertrophic/diagnosis
17.
J Am Heart Assoc ; 13(15): e035993, 2024 Aug 06.
Article in English | MEDLINE | ID: mdl-39056349

ABSTRACT

BACKGROUND: Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM). METHODS AND RESULTS: A total of 282 patients with obstructive hypertrophic cardiomyopathy were randomized 1:1 to daily aficamten (5-20 mg) or placebo between February 1, 2022, and May 15, 2023. Aficamten dosing targeted the lowest effective dose for achieving site-interpreted Valsalva left ventricular outflow tract gradient <30 mm Hg with left ventricular ejection fraction (LVEF) ≥50%. End points were evaluated during titration (day 1 to week 8), maintenance (weeks 8-24), and washout (weeks 24-28), and included major adverse cardiac events, new-onset atrial fibrillation, implantable cardioverter-defibrillator discharges, LVEF <50%, and treatment-emergent adverse events. At week 8, 3.6%, 12.9%, 35%, and 48.6% of patients achieved 5-, 10-, 15-, and 20-mg doses, respectively. Baseline characteristics were similar across groups. Aficamten concentration increased by dose and remained stable during maintenance. During the treatment period, LVEF decreased by -0.9% (95% CI, -1.3 to -0.6) per 100 ng/mL aficamten exposure. Seven (4.9%) patients taking aficamten underwent per-protocol dose reduction for site-interpreted LVEF <50%. There were no treatment interruptions or heart failure worsening for LVEF <50%. No major adverse cardiovascular events were associated with aficamten, and treatment-emergent adverse events were similar between treatment groups, including atrial fibrillation. CONCLUSIONS: A site-based dosing algorithm targeting the lowest effective aficamten dose reduced left ventricular outflow tract gradient with a favorable safety profile throughout SEQUOIA-HCM. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05186818.


Subject(s)
Cardiomyopathy, Hypertrophic , Stroke Volume , Ventricular Function, Left , Humans , Cardiomyopathy, Hypertrophic/physiopathology , Cardiomyopathy, Hypertrophic/drug therapy , Cardiomyopathy, Hypertrophic/diagnosis , Male , Female , Middle Aged , Aged , Ventricular Function, Left/drug effects , Stroke Volume/drug effects , Treatment Outcome , Double-Blind Method , Dose-Response Relationship, Drug , Adult , Atrial Fibrillation/drug therapy , Atrial Fibrillation/diagnosis , Atrial Fibrillation/physiopathology , Benzylamines , Uracil/analogs & derivatives
18.
Arq Bras Cardiol ; 121(7): e202400415, 2024 Jul 26.
Article in Portuguese, English | MEDLINE | ID: mdl-39082572
19.
J Am Coll Cardiol ; 84(6): 602-606, 2024 Aug 06.
Article in English | MEDLINE | ID: mdl-38970597

ABSTRACT

Rest imaging in hypertrophic cardiomyopathy may underestimate or miss left ventricular outflow tract obstruction, leading to suboptimal management decisions that negatively affect symptomatic patients. The 2024 hypertrophic cardiomyopathy guidelines describe exercise stress testing as an important tool to determine overall exercise tolerance and latent, exercise-provoked left ventricular outflow tract obstruction.


Subject(s)
Cardiomyopathy, Hypertrophic , Exercise Test , Ventricular Outflow Obstruction , Humans , Cardiomyopathy, Hypertrophic/physiopathology , Cardiomyopathy, Hypertrophic/complications , Cardiomyopathy, Hypertrophic/diagnosis , Exercise Test/methods , Ventricular Outflow Obstruction/physiopathology , Ventricular Outflow Obstruction/diagnostic imaging , Ventricular Outflow Obstruction/etiology , Male , Middle Aged , Ventricular Outflow Obstruction, Left
20.
Circ Arrhythm Electrophysiol ; 17(7): e012570, 2024 Jul.
Article in English | MEDLINE | ID: mdl-39012930

ABSTRACT

BACKGROUND: Patients with refractory, symptomatic left ventricular (LV) mid-cavity obstructive (LVMCO) hypertrophic cardiomyopathy have few therapeutic options. Right ventricular pacing is associated with modest hemodynamic and symptomatic improvement, and LV pacing pilot data suggest therapeutic potential. We hypothesized that site-specific pacing would reduce LVMCO gradients and improve symptoms. METHODS: Patients with symptomatic-drug-refractory LVMCO were recruited for a randomized, blinded trial of personalized prescription of pacing (PPoP). Multiple LV and apical right ventricular pacing sites were assessed during an invasive hemodynamic study of multisite pacing. Patient-specific pacing-site and atrioventricular delays, defining PPoP, were selected on the basis of LVMCO gradient reduction and acceptable pacing parameters. Patients were randomized to 6 months of active PPoP or backup pacing in a crossover design. The primary outcome examined invasive gradient change with best-site pacing. Secondary outcomes assessed quality of life and exercise following randomization to PPoP. RESULTS: A total of 17 patients were recruited; 16 of whom met primary end points. Baseline New York Heart Association was 3±0.6, despite optimal medical therapy. Hemodynamic effects were assessed during pacing at the right ventricular apex and at a mean of 8 LV sites. The gradients in all 16 patients fell with pacing, with maximum gradient reduction achieved via LV pacing in 14 (88%) patients and right ventricular apex in 2. The mean baseline gradient of 80±29 mm Hg fell to 31±21 mm Hg with best-site pacing, a 60% reduction (P<0.0001). One cardiac vein perforation occurred in 1 case, and 15 subjects entered crossover; 2 withdrawals occurred during crossover. Of the 13 completing crossover, 9 (69%) chose active pacing in PPoP configuration as preferred setting. PPoP was associated with improved 6-minute walking test performance (328.5±99.9 versus 285.8±105.5 m; P=0.018); other outcome measures also indicated benefit with PPoP. CONCLUSIONS: In a randomized placebo-controlled trial, PPoP reduces obstruction and improves exercise performance in severely symptomatic patients with LVMCO. REGISTRATION: URL: https://clinicaltrials.gov/study; Unique Identifier: NCT03450252.


Subject(s)
Cardiac Pacing, Artificial , Cardiomyopathy, Hypertrophic , Cross-Over Studies , Ventricular Function, Left , Humans , Male , Female , Cardiac Pacing, Artificial/methods , Middle Aged , Cardiomyopathy, Hypertrophic/therapy , Cardiomyopathy, Hypertrophic/physiopathology , Cardiomyopathy, Hypertrophic/diagnosis , Treatment Outcome , Aged , Quality of Life , Time Factors , Hemodynamics , Ventricular Outflow Obstruction/physiopathology , Ventricular Outflow Obstruction/therapy , Ventricular Outflow Obstruction/diagnosis , Exercise Tolerance , Ventricular Function, Right , Recovery of Function
SELECTION OF CITATIONS
SEARCH DETAIL